Documento de consenso sobre el uso de los iSGLT2 en el tratamiento de pacientes con diabetes mellitus tipo 2

Garnica-Cuellar, Juan C.; Lavalle-Gonzalez, Fernando J.; Magaña-Serrano, José Antonio; Almeda-Valdés, Paloma; Cetina-Canto, José A; Chávez-Íñiguez, Jonathan S; Garza-García, Carlos A; González-Chávez, Antonio; G, Guillermo González-Gálvez; Medina-Chávez, Juan Humberto; Pimentel-Morales, Gela; Sánchez-Pedraza, Valentín

doi:10.24875/gmm.m21000596

Cited by 2 publications

(1 citation statement)

References 55 publications

(86 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Further, it is frequently accompanied by poor clinical outcomes. In a global context, when compared to other agents that can induce SNS activation, SGLT2i should be more beneficial for the treatment of HF patients [ 53 , 54 ].…”

Section: Hemodynamic Mechanisms Of Sglt2 Inhibitorsmentioning

confidence: 99%

Renal and Cardiovascular Metabolic Impact Caused by Ketogenesis of the SGLT2 Inhibitors

Vargas-Delgado

Herrera

Mite

et al. 2023

IJMS

View full text Add to dashboard Cite

Sodium–glucose cotransporter type 2 inhibitors (SGLT2i) are glycosuric drugs that were originally developed for the treatment of type 2 diabetes mellitus (T2DM). There is a hypothesis that SGLT2i are drugs that are capable of increasing ketone bodies and free fatty acids. The idea is that they could serve as the necessary fuel, instead of glucose, for the purposes of cardiac muscle requirements and could explain antihypertensive effects, which are independent of renal function. The adult heart, under normal conditions, consumes around 60% to 90% of the cardiac energy that is derived from the oxidation of free fatty acids. In addition, a small proportion also comes from other available substrates. In order to meet energy demands with respect to achieving adequate cardiac function, the heart is known to possess metabolic flexibility. This allows it to switch between different available substrates in order to obtain the energy molecule adenosine triphosphate (ATP), thereby rendering it highly adaptive. It must be noted that oxidative phosphorylation in aerobic organisms is the main source of ATP, which is a result of reduced cofactors. These cofactors include nicotine adenine dinucleotide (NADH) and flavin adenine dinucleotide (FADH2), which are the result of electron transfer and are used as the enzymatic cofactors that are involved in the respiratory chain. When there is an excessive increase in energy nutrients—such as glucose and fatty acids—which occur in the absence of a parallel increase in demand, a state of nutrient surplus (which is better known as an excess in supply) is created. The use of SGLT2i at the renal level has also been shown to generate beneficial metabolic alterations, which are obtained by reducing the glucotoxicity that is induced by glycosuria. Together with the reduction in perivisceral fat in various organs, such alterations also lead to the use of free fatty acids in the initial stages of the affected heart. Subsequently, this results in an increase in production with respect to ketoacids, which are a more available energy fuel at the cellular level. In addition, even though their mechanism is not fully understood, their vast benefits render them of incredible importance for the purposes of further research.

show abstract

Section: Hemodynamic Mechanisms Of Sglt2 Inhibitorsmentioning

confidence: 99%

Renal and Cardiovascular Metabolic Impact Caused by Ketogenesis of the SGLT2 Inhibitors

Vargas-Delgado

Herrera

Mite

et al. 2023

IJMS

View full text Add to dashboard Cite

show abstract

Inhibidores del transportador SGLT2 en el tratamiento de la Diabetes mellitus tipo 2: revisión bibliográfica

Orellana Tapia,

Gallegos Mora,

Córdova Orellana

et al. 2024

REVMIC

View full text Add to dashboard Cite

Mellitus Diabetes is a chronic condition that affects the global population. In Latin America, it has high prevalence rates and increasingly rising mortality. In Ecuador, 4,895 deaths from this condition were reported in 2017. Sodium-glucose cotransporter inhibitors (SGLT inhibitors) have been shown to be effective in treating diabetes mellitus. These inhibitors help reduce body weight and glycosylated hemoglobin, particularly in patients with good renal function. SGLT2 inhibitors, approved in recent years, block the renal reabsorption of glucose, promoting its excretion through urine. This reduces blood glucose levels and offers additional benefits such as renal protection and decreased cardiovascular risks. Methodology: Non-experimental, bibliographic review. Objective: Analyze the global benefits of SGLT2 transporter inhibitors in the treatment of type 2 diabetes mellitus. Results: The main SGLT2 inhibitors each have specific pharmacokinetic characteristics and therapeutic applications that can be leveraged when treating patients with this condition. Conclusions: Type 2 diabetes mellitus is a chronic condition that requires timely and appropriate treatment with medications that provide clinical benefits to the patient. Considering SGLT2 inhibitors, a novel treatment approach can be offered to diabetic patients, which is generally well tolerated depending on the patient's condition

show abstract

Documento de consenso sobre el uso de los iSGLT2 en el tratamiento de pacientes con diabetes mellitus tipo 2

Cited by 2 publications

References 55 publications

Renal and Cardiovascular Metabolic Impact Caused by Ketogenesis of the SGLT2 Inhibitors

Renal and Cardiovascular Metabolic Impact Caused by Ketogenesis of the SGLT2 Inhibitors

Inhibidores del transportador SGLT2 en el tratamiento de la Diabetes mellitus tipo 2: revisión bibliográfica

Contact Info

Product

Resources

About